

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia

Information for the public

Published: 7 January 2026

www.nice.org.uk

Venetoclax (Venlyxto) with obinutuzumab (Gazyvaro) is available on the NHS as a possible treatment for untreated chronic lymphocytic leukaemia in adults.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on chronic lymphocytic leukaemia](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Blood Cancer UK](#), 0808 2080 888
- [CLL Support](#), 0800 977 4396
- [Lymphoma Action](#), 0808 808 5555
- [Leukaemia Care](#), 08088 010 444
- [Leukaemia UK](#), 020 8189 9878

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7649-2